Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Executive Vice President & CFO | March 07, 2022 | March 09, 2022 |
| UpHealth, Inc.UPHL · Entity 88003 | Director | January 31, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QUEST DIAGNOSTICS INC
Report date March 07, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,981 |
Ending reported balance
After 2022-03-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-07 · Grant · Acquired 20,780 · Balance 109,456 F1: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). Row 2 · 2022-03-07 · Tax withholding · Disposed 10,475 · Balance 98,981 F2: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d).
F2: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
UpHealth, Inc.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,606 |
Reported balance
After 2024-01-31 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-01-31 · Grant · Acquired 100,000 · Balance 160,606 F2: Subject to the Reporting Person's continued service to the Company, the Restricted Stock Units ("RSUs") shall vest on January 1, 2025; all RSUs shall immediately vest in the event of a Change of Control (as defined in the UpHealth, Inc. 2021 Equity Incentive Plan) of the Company. |
| Common StockSEC Table I · non-derivative | Direct | 60,606 |
Reported balance
Holding disclosure · report date 2024-01-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 60,606 F1: Includes Restricted Stock Units ("Prior RSUs") of UpHealth, Inc. (the "Company"), that are subject to vesting pursuant to previously disclosed vesting schedules. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes Restricted Stock Units ("Prior RSUs") of UpHealth, Inc. (the "Company"), that are subject to vesting pursuant to previously disclosed vesting schedules.
F2: Subject to the Reporting Person's continued service to the Company, the Restricted Stock Units ("RSUs") shall vest on January 1, 2025; all RSUs shall immediately vest in the event of a Change of Control (as defined in the UpHealth, Inc. 2021 Equity Incentive Plan) of the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 1
1 source rowRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.71 · Expires 2028-07-22 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 58,608 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.
F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 2, 2024 18:22 UTC | UpHealth, Inc. UPHL · Entity 88003 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001879 · form4.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,606 F2 · shares: Subject to the Reporting Person's continued service to the Company, the Restricted Stock Units ("RSUs") shall vest on January 1, 2025; all RSUs shall immediately vest in the event of a Change of Control (as defined in the UpHealth, Inc. 2021 Equity Incentive Plan) of the Company. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 09:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 21,096 | Not disclosed Strike: $22.71 | Not disclosed |
DisclosureSEC source: 0001209191-23-017717 · doc4.xml · derivative · entry 5 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 09:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 21,603 | Not disclosed Strike: $21.47 | Not disclosed |
DisclosureSEC source: 0001209191-23-017717 · doc4.xml · derivative · entry 4 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 09:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 58,608 | Not disclosed Strike: $7.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-017717 · doc4.xml · derivative · entry 3 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 58,608 shares Expires 2029-08-22 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 09:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $19.71 | Not disclosed |
DisclosureSEC source: 0001209191-23-017717 · doc4.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2028-07-22 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 09:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerCommon Shares | 3,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-017717 · doc4.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2 · shares: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3 · price: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 20:31 UTC | UpHealth, Inc. UPH · Entity 88003 | GrantCommon Stock | 60,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-024180 · form4.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,606 F1 · balance_after: Subject to the Reporting Person's continued service to UpHealth, Inc. (the "Company"), 1/3 of the Restricted Stock Unit ("RSUs") shall vest on November 22, 2023, and the remaining 2/3 of the RSUs shall vest quarterly on each March 7, May 22, and August 22, of each year such that the RSUs shall be fully vested on November 22, 2025. In the event that Reporting Person's services to the Company ceases prior to any one or more of the vesting dates specified above due to (i) Reporting Person's resignation, (ii) if Reporting Person chooses not to stand for reelection as a member of the Board (if applicable), or F2 · balance_after: (iii) Reporting Person's termination for cause, then such member of the Board will permanently forfeit all RSUs that are unvested as of such date that the services to the Company ceases. However, if Reporting Person's services to the Company ceases due to (i) Reporting Person's termination by the Board other than for cause, (ii) the decision of the Board not to re-nominate Reporting Person for election to the Board (if applicable) other than for cause, (iii) Reporting Person's Disability (as defined in the Plan), or (iv) Reporting Person's death, all RSUs shall immediately vest. In addition, in the event of a Change of Control of the Company (as defined in the Plan), all RSUs shall immediately vest. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 16:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 9,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054816 · doc4.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,859 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person as the annual non-employee director grant. The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time. F2 · shares: Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the "Merger Agreement"). Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:48 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 10,475 | $130.09 | $1,362,692.75 |
DisclosureSEC source: 0001022079-22-000058 · wf-form4_164686249689113.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,981 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:48 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 20,780 | $130.09 | $2,703,270.20 |
DisclosureSEC source: 0001022079-22-000058 · wf-form4_164686249689113.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,456 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 10,932 | $0.00 Strike: $127.73 | $0.00 |
DisclosureSEC source: 0001022079-22-000033 · wf-form4_164609505201179.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,932 Underlying: Common Stock · 10,932 shares Expires 2032-02-24 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-22-000033 · wf-form4_164609505201179.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,676 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 00:08 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 694 | $130.23 | $90,379.62 |
DisclosureSEC source: 0001022079-22-000017 · wf-form4_164583402858760.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,425 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 00:08 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,673 | $130.09 | $217,640.57 |
DisclosureSEC source: 0001022079-22-000017 · wf-form4_164583402858760.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,119 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 17:38 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 21,096 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-21-063677 · doc4.xml · derivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,096 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) November 5, 2022, and (b) the date that is one day prior to the Issuer's 2022 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 21:27 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 6,403 | $115.42 | $739,034.26 |
DisclosureSEC source: 0001022079-21-000054 · wf-form4_161549803034551.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,792 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 21:27 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 17,322 | $115.42 | $1,999,305.24 |
DisclosureSEC source: 0001022079-21-000054 · wf-form4_161549803034551.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,195 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 19, 2018, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 541 | $121.19 | $65,563.79 |
DisclosureSEC source: 0001022079-21-000040 · wf-form4_161428874135843.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,873 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 21:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 830 | $121.15 | $100,554.50 |
DisclosureSEC source: 0001022079-21-000040 · wf-form4_161428874135843.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,414 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of previous grants of restricted share units. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 31,774 | $0.00 Strike: $121.81 | $0.00 |
DisclosureSEC source: 0001022079-21-000019 · wf-form4_161378500022070.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,774 Underlying: Common Stock · 31,774 shares Expires 2031-02-17 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 5,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-21-000019 · wf-form4_161378500022070.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,244 F1 · security: Represents an award of restricted share units. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 21:27 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 81,756 | $66.51 Strike: $66.51 | $5,437,591.56 |
DisclosureSEC source: 0001022079-20-000200 · wf-form4_160919082499081.xml · derivative · entry 4 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,756 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 23, 2020. F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 25, 2017, the second on February 25, 2018 and the final on February 25, 2019. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 21:27 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 22,563 | $121.18 | $2,734,139.21 |
DisclosureSEC source: 0001022079-20-000200 · wf-form4_160919082499081.xml · nonDerivative · entry 3 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,579 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 23, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $120.64 to $121.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 21:27 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 59,193 | $120.06 | $7,106,534.00 |
DisclosureSEC source: 0001022079-20-000200 · wf-form4_160919082499081.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,142 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 23, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.64 to $120.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 21:27 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 81,756 | $66.51 | $5,437,591.56 |
DisclosureSEC source: 0001022079-20-000200 · wf-form4_160919082499081.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 23, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 21,603 | $0.00 Strike: $21.47 | $0.00 |
DisclosureSEC source: 0001209191-20-050879 · doc4.xml · derivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,603 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 72,596 | $71.17 Strike: $71.17 | $5,166,657.32 |
DisclosureSEC source: 0001022079-20-000136 · wf-form4_159182116205657.xml · derivative · entry 5 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,596 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 6, 2020. F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 8,524 | $118.60 | $1,010,980.50 |
DisclosureSEC source: 0001022079-20-000136 · wf-form4_159182116205657.xml · nonDerivative · entry 4 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,579 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 6, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $118.16 to $119.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 18,246 | $117.65 | $2,146,623.65 |
DisclosureSEC source: 0001022079-20-000136 · wf-form4_159182116205657.xml · nonDerivative · entry 3 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,103 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 6, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.15 to $118.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 45,826 | $116.81 | $5,352,980.89 |
DisclosureSEC source: 0001022079-20-000136 · wf-form4_159182116205657.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,349 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 6, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.15 to $117.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 72,596 | $71.17 | $5,166,657.32 |
DisclosureSEC source: 0001022079-20-000136 · wf-form4_159182116205657.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 6, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:58 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,870 | $106.46 | $412,000.20 |
DisclosureSEC source: 0001022079-20-000075 · wf-form4_158404671319326.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,579 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:58 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 7,693 | $106.46 | $818,996.78 |
DisclosureSEC source: 0001022079-20-000075 · wf-form4_158404671319326.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,449 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 00:22 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,195 | $112.90 | $134,915.50 |
DisclosureSEC source: 0001022079-20-000057 · wf-form4_158284932517296.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,756 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 565 | $113.34 | $64,037.10 |
DisclosureSEC source: 0001022079-20-000042 · wf-form4_158275256892243.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,951 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 653 | $112.17 | $73,247.01 |
DisclosureSEC source: 0001022079-20-000042 · wf-form4_158275256892243.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,516 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 40,120 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000028 · wf-form4_158224876751569.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,120 Underlying: Common Stock · 40,120 shares Expires 2030-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 6,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000028 · wf-form4_158224876751569.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,169 F1 · security: Represents an award of restricted share units. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 16:44 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 58,608 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0001209191-19-047529 · doc4.xml · derivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,608 Underlying: Common Shares · 58,608 shares Expires 2029-08-22 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 73,005 | $52.17 Strike: $52.17 | $3,808,305.83 |
DisclosureSEC source: 0001022079-19-000147 · wf-form4_156080369748155.xml · derivative · entry 3 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,005 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 13, 2015, the second on February 13, 2016 and the final on February 13, 2017. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 73,005 | $100.00 | $7,300,500.00 |
DisclosureSEC source: 0001022079-19-000147 · wf-form4_156080369748155.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,017 Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 73,005 | $52.17 | $3,808,305.83 |
DisclosureSEC source: 0001022079-19-000147 · wf-form4_156080369748155.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 5,288 | $86.86 | $459,315.68 |
DisclosureSEC source: 0001022079-19-000091 · wf-form4_155182141718438.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,017 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 10,736 | $86.86 | $932,528.96 |
DisclosureSEC source: 0001022079-19-000091 · wf-form4_155182141718438.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,305 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:21 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,556 | $87.84 | $136,679.04 |
DisclosureSEC source: 0001022079-19-000074 · wf-form4_155139245730159.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,569 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 660 | $88.24 | $58,238.40 |
DisclosureSEC source: 0001022079-19-000060 · wf-form4_155131017859571.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,125 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 00:58 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 610 | $88.39 | $53,917.90 |
DisclosureSEC source: 0001022079-19-000042 · wf-form4_155114267401719.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,785 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:26 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 63,259 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000022 · wf-form4_155070518922803.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,259 Underlying: Common Stock · 63,259 shares Expires 2029-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:26 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 5,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000022 · wf-form4_155070518922803.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,395 F1 · shares: Represents an award of restricted share units. Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:10 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001209191-18-043812 · doc4.xml · derivative · entry 1 GUINAN MARK · CIK 0001505998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2028-07-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on July 23, 2019, with the balance of the shares vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.